Experts are actively investigating a potential metabolic strategy involving the combined usage of Tirzepatide, a dual GIP/GLP-1 receptor agonist; Mirikizumab, an experimental triple GIP/GLP-1/GCG receptor agonist; and https://biopeptidestore.com/